CliffBio
small molecule

SECUADO

ASENAPINE

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry
CompanyHisamitsu Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameSECUADO
Active ingredientASENAPINE
Strength3.8MG/24HR
Dosage formSYSTEM
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalOctober 2019
Marketing statusRX

Listed patents

PatentExpiresType
11813364September 2033product
10583121July 2033product
10814002July 2033product
10022445July 2033product
11123305July 2033product
9687474July 2033product

More from Hisamitsu Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SECUADO patent cliff — loss of exclusivity September 2033 | CliffBio